Product Roadmap

Four stages from foundation to expansion

Each milestone carries its honest status. Most of the value in this company sits in stages two and three, and we present them as work to be done, not work already done.

CompletedUnderwayPlanned
Stage 1

Foundation

  • Select the initial productUnderway
  • Validate healthcare customer needsUnderway
  • Develop the MVPUnderway
  • Establish technical architectureCompleted
  • Research regulatory requirementsUnderway
Stage 2

Validation

  • Conduct product demonstrationsUnderway
  • Obtain pilot customersPlanned
  • Improve product usabilityPlanned
  • Validate pricingPlanned
  • Test customer acquisition channelsUnderway
Stage 3

Commercialization

  • Launch the initial productPlanned
  • Introduce subscription plansPlanned
  • Build customer supportPlanned
  • Develop integration capabilitiesPlanned
  • Establish recurring revenuePlanned
Stage 4

Expansion

  • Expand product functionalityPlanned
  • Develop additional healthcare modulesPlanned
  • Explore strategic integrationsPlanned
  • Expand US market distributionPlanned
  • Evaluate additional healthcare marketsPlanned

How to read this roadmap

One item is marked completed: the technical architecture the products are being built on. Foundation and validation work is underway, including customer-needs validation, MVP development, regulatory research, product demonstrations and acquisition channel tests. Everything in commercialization and expansion is planned. Timelines depend on the funding round described on the funding page, and this page will be updated as statuses change.

Help us move the roadmap faster

The pre-seed round exists to turn the underway column into the completed one, and to start commercialization on evidence rather than hope.

Investor information disclaimer. MedClinicX is an early-stage, pre-seed company and is not currently generating revenue. The information on these pages is provided for general information and relationship building. It is not a public offering of securities, and it is not investment advice. No valuation, equity percentage, investment return or exit is promised or implied. Figures labelled as projections, assumptions, illustrations or targets are forward looking statements about what the company intends to pursue, not results that have been achieved. Anyone considering an investment should carry out their own review and take independent professional advice. Please also read our Privacy Policy and Terms of Service.